A reverse phase high performance liquid chromatographic (RP-HPLC) method was developed and validated as per ICH guidelines for the analysis of Pranlukast in its capsule form. The analysis was performed on a C-18 column. Separation was completed isocratically by using a mobile phase of phosphate buffer and Ethylnitrile in 60:40 ratio at 30ºC and maintained at a flow rate of 1 millilitre per minute. Ultraviolet absorption was maximum at 238 nanometre wavelength. Linearity was satisfied in the range 28.125 ppm to 168.75 ppm, with correlation coefficient value of 0.999. The percent relative standard deviation for precision, accuracy and robustness were less than two. The limit of detection and limit of quantification were 0.07 ppm and 0.21 ppm respectively. All the validation results were within the acceptance limits
